PDMR Dealings

Oxford Biomedica PLC

11 October 2023

 

Director Dealing

Oxford, UK - 11 October 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces that Namrata Patel, a Non-Executive Director of the Company, has purchased 1,670 ordinary shares in the Company. The following table sets out the number of shares purchased and additional details.

Name of PDMR	Number of ordinary shares purchased	Number of ordinary shares now held	Total number of ordinary shares held as a percentage of the Company's share capital
Namrata Patel	1,670	9,170	0.009%

The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")
a)	Name	Namrata Patel
2.	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Purchase of shares
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £2.99 1,670
e)	Aggregated information -    Aggregate volume -    Aggregated total	1,670 £4,993.30
f)	Date of the transaction	2023-10-09
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com, www.oxbsolutions.com, and follow us on LinkedIn and YouTube.

 

END